Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | dihydrofolate reductase | 0.0363 | 1 | 1 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0363 | 1 | 0.5 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.0363 | 1 | 1 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0139 | 0.3372 | 0.5 |
Echinococcus multilocularis | dihydrofolate reductase | 0.0363 | 1 | 1 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.0363 | 1 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.0363 | 1 | 1 |
Echinococcus granulosus | dihydrofolate reductase | 0.0363 | 1 | 1 |
Brugia malayi | Cation transporter family protein | 0.0081 | 0.1662 | 0.1662 |
Schistosoma mansoni | nAChR subunit (ShAR1-beta-like) | 0.0081 | 0.1662 | 0.1662 |
Onchocerca volvulus | 0.0081 | 0.1662 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0081 | 0.1662 | 0.1662 |
Chlamydia trachomatis | dihydrofolate reductase | 0.0363 | 1 | 0.5 |
Onchocerca volvulus | 0.0081 | 0.1662 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0081 | 0.1662 | 0.1662 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.0363 | 1 | 0.5 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0139 | 0.3372 | 0.5 |
Onchocerca volvulus | 0.0081 | 0.1662 | 1 | |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0139 | 0.3372 | 0.5 |
Schistosoma mansoni | nAChR subunit (ShAR1-alpha-like) | 0.0081 | 0.1662 | 0.1662 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0139 | 0.3372 | 0.5 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0139 | 0.3372 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.007 | 0.1324 | 0.1324 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0139 | 0.3372 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.